Acquista Criptovalute
Paga con
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Mercati
Trading
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Opzioni
Hot
Trade European-style Vanilla Options
Conto unificato
Massimizza l'efficienza del tuo capitale
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Guadagna
Lancia
CandyDrop
Raccogli le caramelle per guadagnare airdrop
Launchpool
Staking rapido, guadagna potenziali nuovi token
HODLer Airdrop
Fai holding GT e ottieni enormi airdrop gratuitamente
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investimento
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
Altro
Promozioni
AI
Altro
TradFi
WCTC S8
Rewards
IBIT

Prezzo iShares Bitcoin Trust

IBIT
$0
+$0(0,00%)
Nessun dato

*Data last updated: 2026-04-28 22:08 (UTC+8)

As of 2026-04-28 22:08, iShares Bitcoin Trust (IBIT) is priced at $0, with a total market cap of --, a P/E ratio of 0,00, and a dividend yield of 0,00%. Today, the stock price fluctuated between $0 and $0. The current price is 0,00% above the day's low and 0,00% below the day's high, with a trading volume of --. Over the past 52 weeks, IBIT has traded between $0 to $0, and the current price is 0,00% away from the 52-week high.

IBIT Key Stats

P/E Ratio0,00
Dividend Yield (TTM)0,00%
Shares Outstanding0,00

Ulteriori informazioni su iShares Bitcoin Trust (IBIT)

Blogs

R2xpIGFmZmx1c3NpIG5ldHRpIGRlZ2xpIEVURiBzdSBCaXRjb2luIHN1cGVyYW5vIGkgNTggbWlsaWFyZGkgZGkgZG9sbGFyaTogY2lucXVlIHNlZ25hbGkgY2hpYXZlIHBlciBsYSBsaXF1aWRpdMOgIGRpIG1lcmNhdG8=

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

2026-04-28

IyBHbGkgYWZmbHVzc2kgbmV0dGkgc2V0dGltYW5hbGkgbmVnbGkgRVRGIHNwb3Qgc3UgQml0Y29pbiBzdXBlcmFubyBnbGkgODAwIG1pbGlvbmkgZGkgZG9sbGFyaSwgSUJJVCBkaSBCbGFja1JvY2sgY29udGludWEgYSBkb21pbmFyZSBpbCBtZXJjYXRv

TOKAmWFmZmx1c3NvIG5ldHRvIHNldHRpbWFuYWxlIG5laSBCaXRjb2luIFNwb3QgRVRGIHJhZ2dpdW5nZSA4MjMgbWlsaW9uaSBkaSBkb2xsYXJpLCBJQklUIGRpIEJsYWNrUm9jayBjb250aW51YSBhIGd1aWRhcmUgaWwgbWVyY2F0by4gQW5hbGlzaSBhcHByb2ZvbmRpdGEgZGVpIGNhbWJpYW1lbnRpIG5lbGxhIHN0cnV0dHVyYSBkZWwgY2FwaXRhbGUgaXN0aXR1emlvbmFsZSBlIGRlbGzigJlpbXBhdHRvIHN1bCBtZXJjYXRvLg==

2026-04-27

Uml0cmFjY2lhbWVudG8gZGVsIEJpdGNvaW4gZGVsIDI1JSBwb3J0YSBhIDgsNCBtaWxpYXJkaSBkaSBkb2xsYXJpIGRpIGFmZmx1c3NpIGluIElCSVQ6IHBlcmNow6kgbGUgaXN0aXR1emlvbmkgY29udGludWFubyBhZCBhY3F1aXN0YXJlIEVURj8=

TmVsIHByaW1vIHRyaW1lc3RyZSBkZWwgMjAyNiwgQml0Y29pbiBoYSByZWdpc3RyYXRvIHVuIGNhbG8gc3VwZXJpb3JlIGFsIDI1JS4gVHV0dGF2aWEsIGzigJlJQklUIGRpIEJsYWNrUm9jayBoYSBzZWduYXRvIGFmZmx1c3NpIG5ldHRpIGluIDQ4IGRlbGxlIDYyIGdpb3JuYXRlIGRpIG5lZ296aWF6aW9uZSwgY29uIGFmZmx1c3NpIG5ldHRpIHRvdGFsaSBjaGUgaGFubm8gcmFnZ2l1bnRvIGNpcmNhIDgsNCBtaWxpYXJkaSBkaSBkb2xsYXJpIG5lbCB0cmltZXN0cmUu

2026-04-27

iShares Bitcoin Trust (IBIT) FAQ

What's the stock price of iShares Bitcoin Trust (IBIT) today?

x
iShares Bitcoin Trust (IBIT) is currently trading at $0, with a 24h change of 0,00%. The 52-week trading range is $0–$0.

What are the 52-week high and low prices for iShares Bitcoin Trust (IBIT)?

x

What is the price-to-earnings (P/E) ratio of iShares Bitcoin Trust (IBIT)? What does it indicate?

x

What is the market cap of iShares Bitcoin Trust (IBIT)?

x

What is the most recent quarterly earnings per share (EPS) for iShares Bitcoin Trust (IBIT)?

x

Should you buy or sell iShares Bitcoin Trust (IBIT) now?

x

What factors can affect the stock price of iShares Bitcoin Trust (IBIT)?

x

How to buy iShares Bitcoin Trust (IBIT) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

IBIT
CFD
Fai trading

iShares Bitcoin Trust (IBIT) Latest News

2026-04-28 16:31

Colombia's Largest Pension Fund Launches Bitcoin ETF Product with $25 Minimum Investment

Gate News message, April 28 — Porvenir, Colombia's largest pension fund manager, has launched a Bitcoin investment product offering indirect exposure to BTC through BlackRock's spot Bitcoin ETF (IBIT). The "Crypto Porvenir Portfolio" is designed for voluntary retirement accounts, with a minimum investment of approximately 100,000 Colombian pesos (about $25), making Bitcoin investment accessible to a broader range of investors. The product tracks Bitcoin price through the iShares Bitcoin Trust (IBIT), which manages over $50 billion in assets. By investing through the structured ETF rather than purchasing Bitcoin directly, investors avoid risks associated with managing digital wallets, such as cyberattacks or password loss.

2026-04-28 12:39

BlackRock Transfers 6,040 ETH and 362 BTC to Major CEX

Gate News message, April 28 — BlackRock transferred 6,040 ETH worth approximately $13.79 million to a major CEX via its Ethereum ETF (ETHA) approximately one hour ago. The investment firm also moved 362.682 BTC, valued at approximately $27.73 million, to the same CEX through its Bitcoin ETF (IBIT).

2026-04-28 02:31

Colombia's Largest Pension Fund Porvenir Launches Crypto Investment Portfolio

Gate News message, April 28 — Porvenir, Colombia's largest pension fund manager, has launched a cryptocurrency investment portfolio allowing members to gain indirect exposure to Bitcoin through a regulated mechanism. The product operates via BlackRock's Bitcoin ETF (IBIT) with a minimum investment of 100,000 Colombian pesos (approximately $25). The offering targets savers aged 18 to 45 and is limited to the voluntary pension system, separate from mandatory basic pension savings. Members are required to undergo mandatory personalized consultations to confirm their risk tolerance before participating. Porvenir joins competitor Protección, another Colombian pension manager, which previously introduced a similar crypto investment product.

2026-04-27 05:14

BlackRock Bitcoin ETF IBIT Posts $983M Net Inflows in Past Week, Marking 6-Month High

Gate News message, April 27 — According to CryptoQuant data, BlackRock's Bitcoin ETF IBIT recorded net inflows of $983 million over the past week, marking the highest level in the past six months. Driven by inflows into IBIT and other spot Bitcoin ETFs, BTC has shown strong performance, with gains of nearly 18% accumulated throughout April.

2026-04-26 04:17

Bitcoin Spot ETFs Record $144.49M Net Inflows for 9 Consecutive Days, BlackRock IBIT Leads

Gate News message, April 26 — Bitcoin spot ETFs recorded total net inflows of $144.489 million on April 25, extending a streak of nine consecutive days of positive flows, according to SoSoValue data. BlackRock's IBIT led all funds with single-day net inflows of $22.879 million, bringing its cumulative net inflows to $190 million. Morgan Stanley's MSBT followed with $11.1294 million in single-day inflows and $153 million in historical total net inflows. Ark Invest and 21Shares' ARKB recorded the largest single-day outflows at $9.016 million, though it maintains $1.61 billion in cumulative net inflows. As of press time, total bitcoin spot ETF assets under management reached $102.637 billion, with the ETF net asset ratio (market value relative to total bitcoin market cap) at 6.6%. Cumulative net inflows since inception have reached $58.564 billion.

Hot Posts su iShares Bitcoin Trust (IBIT)

discovery

discovery

34 minuti fa
#CryptoMarketsDipSlightly 📉 Minor pullback, not a breakdown What happened today: Total Market Cap: $2.60T – $2.64T, down ∼1.8% in 24h Bitcoin: $77,593, -0.66% today after hitting $79,485 high Ethereum: Slipped below $2,300, trading around $2,314 Crypto ETFs: GSR Crypto Core3 -1.94%, Fidelity Crypto Industry -1.37 Why the slight dip? 4 factors: Profit-taking after $79K rejection BTC hit $79,472 then got capped. Bears defending the $80K psychological level hard. Traders locking in gains after April’s 13.6% rally. Fed meeting jitters Market is “cautiously optimistic” ahead of the Fed rate decision. Rate uncertainty = de-risking. Fed’s Waller said “crypto hype is fading” as TradFi ties increase sell pressure. Leverage reset + liquidations $273M liquidated in 24h, $183M were longs. Traders got too bullish expecting $74K+ breakout. Liquidations triggered cascade selling. This is healthy - resets leverage before next move. Altcoins weaker than BTC Altcoin market cap saw 3.58% intraday drop. TRUMP -10%, METIS -12.8%, BANANA -12%. Capital rotating back to BTC which acts as liquidity anchor. Context – This is normal: Sentiment index rose to 47, neutral territory. Market calls this a “controlled pullback” and “post-expansion cooldown”. Not breakdown, just consolidation. Fear & Greed sits at 33, “Fear”. Meanwhile ETF inflows still strong: $2.1B over 8 days, BlackRock IBIT fastest-growing ETF ever. Key levels to watch: BTC Support: $76,829 = $878M long liquidations, $72K-$73K major zone BTC Resistance: $79,178 = $841M short liquidations, then $80K If $74,142 breaks: $916M long liquidation risk Bottom line: Slight dip = profit-taking + Fed uncertainty + leverage flush. Capital hasn’t left, just rotating. Structure still bullish if $72K holds. Buying the dip or waiting for $76K? $BTC $GT
BTC-0,77%
ETH-0,08%
TRUMP-0,27%
METIS-0,16%
4
6
0
0
CoffeeNFTrader

CoffeeNFTrader

43 minuti fa
- Advertisement -![](https://img-cdn.gateio.im/social/moments-d051814f15-4440bc6166-8b7abd-badf29) * * * * * U.S. spot crypto ETFs ended December 24 with a clear split in investor behavior, as capital moved out of Bitcoin and Ethereum products while Solana and XRP funds attracted fresh inflows. The data, published by SoSoValue, highlights a cautious shift in positioning rather than broad-based risk appetite. ### Bitcoin ETFs Lead Daily Outflows Spot Bitcoin ETFs recorded $175 million in total net outflows on the day, marking one of the larger single-day withdrawals late in the year. The pullback was driven primarily by IBIT, BlackRock’s spot Bitcoin ETF, which posted $91.37 million in net outflows — the largest decline among all Bitcoin ETF products. ![](https://img-cdn.gateio.im/social/moments-b8b5da35b1-f81e718092-8b7abd-badf29) Other major funds also saw redemptions, including Grayscale’s GBTC, Fidelity’s FBTC, and Bitwise’s BITB, each contributing to the overall negative flow. Despite these daily outflows, cumulative net inflows for several Bitcoin ETFs remain positive, suggesting the move reflects short-term caution rather than a structural exit. ### Ethereum ETFs Also See Redemptions Spot Ethereum ETFs followed a similar pattern, with $52.70 million in total net outflows. Grayscale-backed products accounted for the bulk of the selling pressure, while most other Ethereum ETFs saw flat or neutral daily flows. ![](https://img-cdn.gateio.im/social/moments-3c9f1131dd-09bd711861-8b7abd-badf29) The data shows that Ethereum ETF activity remains more muted overall, with fewer funds recording meaningful inflows or outflows compared to Bitcoin products. ### Gold Leads the Cycle – Bitcoin Historically Follows: What Could be Next? ### Solana and XRP Stand Out In contrast to Bitcoin and Ethereum, Solana spot ETFs recorded net inflows of $1.48 million, signaling selective interest in alternative Layer 1 exposure. XRP spot ETFs also posted positive flows, with $11.93 million in net inflows, making XRP one of the strongest performers among U.S. spot crypto ETFs on the day. This divergence suggests investors are reallocating within the crypto ETF space rather than reducing exposure across the board. ### What the Data Suggests The snapshot points to rotation, not retreat. Bitcoin and Ethereum ETFs experienced near-term profit-taking or defensive positioning, while capital selectively moved into Solana and XRP products. Premiums and discounts across funds remained modest, indicating orderly market conditions rather than stress. As year-end approaches, ETF flows continue to reflect tactical allocation decisions, with investors adjusting exposure across assets instead of exiting the crypto market entirely.
BTC-0,77%
ETH-0,08%
SOL-0,66%
XRP-0,86%
0
0
0
0
BraveNewCoin

BraveNewCoin

49 minuti fa
On April 16, Health and Human Services Secretary Robert F. Kennedy Jr. confirmed the FDA will convene its Pharmacy Compounding Advisory Committee in July to reconsider a slate of peptides the Biden-era FDA designated as “Category 2” — bulk drug substances flagged for “significant safety risks.” A second panel is scheduled for February 2027. Twelve peptides are on the docket: BPC-157, Thymosin beta-4 fragment (LKKTETQ), Epitalon, GHK-Cu (injectable), MOTS-c, DSIP, Dihexa Acetate, Ibutamoren Mesylate, Melanotan II, KPV, Semax, and Cathelicidin LL-37. ![The peptide market is on track to add roughly $130 billion in value over the next decade with or without Kennedy's Category 2 reversal. The reversal just determines who captures it — regulated U.S. compounders and telehealth platforms, or offshore vendors with TikTok storefronts.](https://bravenewcoin.com/wp-content/uploads/2026/04/Screenshot-2026-04-29-at-9.03.34-AM-1024x631.png) *Today, we took long-overdue action to restore science, accountability, and the rule of law, said Kennedy, source: X* To anyone who watched crypto’s regulatory cycle, the political economy is recognizable. A previous administration treated the category as inherently suspect and pushed users offshore. A new administration argues the restriction created the very problem it was meant to solve and is reopening the regulated channel. “We will follow the science, enforce the law, and deliver the clarity patients, providers, and pharmacies deserve,” Kennedy said in his April statement. Critics aren’t convinced. “Everybody knows the outcome that the secretary wants,” Peter Lurie, a former FDA associate commissioner, told NBC News, arguing the review is unlikely to produce honest scrutiny. Bitcoin maximalists made the same argument about the SEC’s 2024 about-face, and the price action didn’t care. ## The setup, in markets terms Peptide therapeutics — short chains of amino acids that act as biological signaling molecules — are not a fringe category. The global market was valued at roughly $141 billion in 2025 and is projected to reach about $164 billion this year, on track to nearly double to $295 billion by 2033. Insulin is a peptide. So is semaglutide. So is tirzepatide. The branded, FDA-approved end of the market is one of pharma’s largest and fastest-growing categories. The contested end — the twelve compounds on Kennedy’s list — sits in the same regulatory shadow that offshore crypto exchanges occupied circa 2022. Compounding pharmacies were preparing peptides under the FDA’s Section 503A framework until the 2023 Category 2 reclassification effectively shut them out. Demand didn’t disappear; it routed offshore. TikTok and Telegram vendors now sell vials labeled “research use only” for as little as $5, most of them sourced from Chinese laboratories outside U.S. drug standards. The parallel to unregulated offshore exchanges, sanctions-evading mixers, and crypto’s grey supply chain isn’t subtle. The regulated US channel got squeezed; demand migrated to jurisdictions where quality is whatever the seller says it is. The retail demand signal is also familiar. Google search interest in “peptides” rose 80% in the United States between April 2025 and April 2026, according to trend data compiled by Open Loop Health, with queries for “cost of peptide therapy” up 300%. Joe Rogan and Andrew Huberman are doing for BPC-157 what Michael Saylor and Anthony Pompliano did for Bitcoin: pulling a category into mainstream consciousness through high-trust audiences well before the regulatory framework catches up. ## The spot-ETF moment What makes this more than a wellness trend is what’s happening at the institutional end of the same molecule class. Eli Lilly’s investigational triple-receptor agonist retatrutide — itself a synthetic peptide — has produced the most dramatic obesity trial results on record. In December, Lilly’s TRIUMPH-4 study reported average weight loss of up to 23.7% (about 60 pounds) at the highest dose over 68 weeks, alongside significant reductions in osteoarthritis knee pain. A March 2026 Type 2 diabetes readout showed up to 17% weight loss and 2-point A1c reductions at 40 weeks. Seven additional Phase 3 readouts are expected through year-end, with FDA filing anticipated Q4 2026 or Q1 2027. For peptides as an asset class, retatrutide is the equivalent of BlackRock filing for IBIT. Once a major institution proves the thesis can clear the highest bar — a Phase 3 trial, a spot ETF — the category gets re-rated. Capital that previously stayed away on credibility grounds starts looking for adjacent exposure. The wider peptide thesis no longer rests on Rogan-podcast anecdotes; it rests on data from a $700 billion drugmaker. ## The investable surface The publicly tradable proxies are already moving. Hims & Hers shares jumped on Kennedy’s April announcement on the view that compounded peptides could become the next growth lane after GLP-1s, with Leerink calling it a clearer regulatory path to scale. The setup mirrors the Coinbase trade: a public-equity vehicle whose valuation tracks the regulatory tailwind for the underlying category. The infrastructure layer is moving harder. Lilly is committing more than $6 billion to a new active pharmaceutical ingredient plant in Huntsville, Alabama, with peptide manufacturing as a core mandate. CordenPharma, Cambrex, and Lupin Manufacturing Solutions have all expanded peptide capacity in the past 12 months. In capital-allocation terms, this is the Strategy / Marathon move — operators making multi-billion-dollar bets on a category continuing to compound for a decade. Branded peptide therapeutics already account for more than 60% of the segment’s revenue, with North America holding roughly 38% of the global market. ## Where crypto and peptides actually overlap There is also a direct on-chain expression of the peptide thesis. VitaDAO, the decentralized longevity-research collective, has spent the past several years funding early-stage aging and longevity science through community governance, with its VITA token coordinating treasury decisions. PoSciDonDAO, profiled previously by BNC, runs a similar model for personalized medicine research funding. The Venn diagram between crypto-native investors and longevity bettors — Bryan Johnson’s audience, the Rogan-Huberman demographic, the Balaji Srinivasan thesis — overlaps almost entirely. DeSci tokens are, in a real sense, the only liquid way to express a longevity-science thesis at the protocol level. As the peptide category re-rates, that adjacent on-chain market is one of the more interesting beta plays on the same macro story. ## The top six on the slate Of the twelve peptides under FDA review, six dominate the clinical and consumer conversation: **BPC-157** — Synthetic fragment of a gastric-juice protein, used for tendon, ligament, and gut healing. Animal data extensive, human trials sparse. Almost certainly the headline name at the July panel. **GHK-Cu (copper peptide)** — Naturally occurring tripeptide used both in skincare and as an injectable for wound healing and skin remodeling. Among the better-evidenced peptides on the list. **Epitalon** — Soviet-developed four–amino-acid peptide marketed as a telomerase activator. Thin human data, mostly from a single research group. Flagship of the longevity-clinic circuit. **MOTS-c** — Mitochondrial-derived peptide with credible academic interest in metabolic regulation and exercise mimicry. Mechanistic story is strong; Phase 3 data does not yet exist. **Thymosin beta-4 fragment (LKKTETQ)** — Active fragment of TB-500, used for soft-tissue repair. Parent compound studied in early cardiac and corneal trials. **Ibutamoren (MK-677)** — Technically a non-peptide growth-hormone secretagogue but bundled with the cohort. Clearest pharmacology, most documented side effects: water retention, insulin resistance, increased appetite. The remaining six — DSIP, Dihexa, Melanotan II, KPV, Semax, and Cathelicidin LL-37 — span sleep, cognition, tanning, gut inflammation, and antimicrobial defense. ## Risks that should sound familiar The bear case mirrors crypto’s. The advisory committee is non-binding; rulemaking takes months; the FDA panel currently has multiple vacancies Kennedy can fill before July, raising legitimate process concerns. Most of the twelve peptides have minimal Phase 3 human data and no patent path that would justify building one. Quality control in the existing market is poor — counterparty risk in peptide vials is a meaningful problem the way self-custody-vs-exchange risk is in crypto. And political reversibility cuts both ways: what one administration unlocks, another can re-restrict. What the bull case has going for it is the same thing crypto’s bull case had in early 2024: real capital is being deployed against the thesis at scale. Lilly’s $6 billion plant doesn’t get built on a regulatory whim. The peptide market is on track to add roughly $130 billion in value over the next decade with or without Kennedy’s Category 2 reversal. The reversal just determines who captures it — regulated U.S. compounders and telehealth platforms, or offshore vendors with TikTok storefronts. For investors looking past the next quarter, the trade isn’t whether peptides matter. It’s whether the legitimate end of the supply chain finally gets to participate.
0
0
0
0